Last updated: May 26, 2026
Teriflunomide suppliers: who manufactures bulk drug substance and finished doses for global markets
Teriflunomide’s supply chain splits into (1) bulk drug substance (API) manufacture and (2) finished-dose tablets marketed under branded and generic labels. The most decision-relevant “suppliers” are the labeled finished-dose manufacturers listed by FDA for US marketing and the API producers tied to major abbreviated new drug applications (ANDAs) and dossiers worldwide.
Which companies supply teriflunomide API and who makes bulk drug substance?
Teriflunomide (active ingredient) is typically produced by pharmaceutical chemical manufacturers that supply global API distributors and ANDA filers. In commercial practice, API sourcing can change across lifecycle stages because distributors qualify new supply, and generic filers select whichever API source supports cost and regulatory readiness.
How to map API suppliers in practice
- Track ANDA applicants and the associated drug master file (DMF) references for teriflunomide (API) used for US filings.
- Cross-check whether branded products (US: Aubagio) list a US manufacturer/labeler and whether that aligns with the API DMF.
- For non-US markets, map API producers via national marketing authorizations and dossier procurement patterns (EU/UK tend to show manufacturing sites at the marketing authorization holder level).
Who are the FDA-labeled finished-dose manufacturers for teriflunomide tablets?
For the US, the key “supplier” role is the FDA labeler/manufacturer of record for the teriflunomide tablets product(s) on the Orange Book. The labeler is what matters for:
- US distribution planning,
- launch preparedness for generics,
- and enforcement work (who can be served in a US litigation context).
Branded reference product
- Aubagio (teriflunomide) tablets: labeler and manufacturer of record can be pulled from FDA’s Orange Book label/approval data and prescribing label “Manufactured for” statements.
Generic products
- Each ANDA product has an FDA labeler/manufacturer of record. These labelers are the practical “suppliers” for pharmacy channels in the US because wholesalers typically source from the labeled product, not directly from an API producer.
What Orange Book status does teriflunomide have, and who supplies products during exclusivity?
Orange Book status determines which products are:
- the reference listed drug(s) (RLD),
- protected for patent and exclusivity,
- and the period when generic entry is more constrained.
What to extract from the Orange Book for supplier decisions
- RLD listing and labeler/manufacturer details.
- Patent-expiration and exclusivity blocks that affect generic launch timing.
- ANDA product list, including labelers currently supplying US markets.
When do teriflunomide exclusivity and patent protections end, and how does that affect supply?
Exclusivity and patent expiration affect supply primarily by changing:
- the feasibility of Paragraph IV challenges,
- the readiness window for generic launches,
- and licensing-linked supply guarantees if settlement exists.
Supplier impact
- Prior to expiration, branded and any authorized generics are the dominant supply.
- Post-expiration, multiple ANDAs can supply, often with at least two distinct manufacturing networks (tablet manufacturing and API sources).
Which suppliers produce teriflunomide generics in the US market?
Generic supply is determined by:
- ANDA applicants that received approval, and
- the labeler and manufacturing site listed for each approved ANDA.
A complete supplier list requires Orange Book product-level extraction by ANDA, including:
- applicant (who files),
- labeler (who markets under the NDC),
- manufacturer of record (who makes tablets in the formulation step),
- and whether multiple NDCs exist for different strengths or package types.
What patent estate constraints affect teriflunomide supply chains and manufacturing sites?
Teriflunomide’s patent estate typically governs:
- compound claims (active ingredient),
- formulation/solid form claims (tablet composition),
- method-of-use claims (label indications),
- and sometimes manufacturing-process claims.
Supplier risk areas
- If a generic filer relies on a formulation route that triggers process or solid-state IP, it may face an injunction risk post-approval.
- Formulation patents can constrain tablet excipient systems, coatings, or dissolution performance targets, which affects which formulation CMOs can qualify a commercial process.
What formulatory and manufacturing capabilities are required to supply teriflunomide tablets?
Teriflunomide is supplied as tablets. Tablet supply requires:
- blending and granulation controls,
- validated tablet pressing and coating lines,
- dissolution and content-uniformity validation,
- stability programs aligned with labeled shelf-life.
Practical CMO/contract manufacturing implications
- Not all tablet CMOs can reliably reproduce dissolution profiles that pass ANDA bioequivalence bridging requirements.
- Supplier qualification tends to concentrate among CMOs experienced with narrow dosing tolerances and extended-term stability.
How does teriflunomide biosimilar risk apply, and what does it mean for suppliers?
Teriflunomide is a small-molecule drug, not a biologic. Biosimilar frameworks do not apply in the same way as for monoclonal antibodies or recombinant proteins.
Implication for supplier landscape
- Competition is through ANDAs and generic chemical/solid dosage manufacturing, not biosimilar comparability.
Which companies challenge teriflunomide patents via Paragraph IV and how does that change supplier rosters?
Paragraph IV filings typically identify:
- the ANDA challenger,
- the nature of the certification (I, II, III, IV),
- and timing for potential launch.
Supplier outcome
- A successful settlement can bind launch entry, sometimes via “authorized generic” arrangements or exclusivity carve-outs that affect who supplies during the post-launch period.
What generic entry risks exist for teriflunomide supply, including formulation or labeling disputes?
Key entry risks impacting supply:
- patent injunctions tied to Orange Book-listed patents,
- settlement terms that delay entry,
- label or indication carve-outs affecting market access,
- supply disruptions when a primary manufacturing site has batch failures or fails inspection.
How does teriflunomide compare to other multiple sclerosis oral therapies in supplier and generic readiness?
Teriflunomide sits in the oral MS category alongside drugs like dimethyl fumarate, fingolimod, and others with differing exclusivity timelines and manufacturing complexity. Supplier readiness depends on:
- ease of solid-dose replication,
- strength-specific dissolution requirements,
- and how quickly major tablet CMOs can qualify ANDA-grade APIs.
Key Takeaways
- Teriflunomide “suppliers” in practice mean two layers: FDA-labeled tablet manufacturers (US channel supply) and API producers tied to DMFs/ANDA dossiers (input supply).
- Supplier selection for generics hinges on ANDA labeler/manufacturer of record, not only API producers.
- Orange Book listings (RLD, patents, and ANDA approvals) drive the timing of supply expansion after exclusivity/patent barriers.
- Litigation and settlements tied to Paragraph IV certifications can materially change which manufacturers supply in the first post-patent window.
FAQs
- How do I identify teriflunomide tablet manufacturers for specific NDCs in the US?
- Which teriflunomide ANDA applicants are approved for each strength and dosage form?
- Does teriflunomide require DMF-based API sourcing for generic approval?
- What manufacturing site approvals matter most for teriflunomide tablet ANDAs?
- What Orange Book patents typically govern teriflunomide generic launch timing?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA: Teriflunomide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Label information for Aubagio (teriflunomide). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
